Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
31 pending office actions • 18 clients • 27 examiners • 22 art units • 0 of 31 (0%) have an AI response strategy ready
HAUG PARTNERS LLP specializes in Biotechnology & Pharmaceuticals, managing 7879 career applications. The firm has a resolved allowance rate of 82.06 percent. On average, the firm receives 3.65 office actions per allowance during prosecution.
The firm currently has 27 pending office actions. The 82.06 percent allowance rate across 7879 career applications demonstrates a solid level of success in the biotech sector. With 3.65 average office actions per allowance, the firm shows a persistent approach to securing patent rights for its clients. This experience is vital for the firm as it manages the 27 pending office actions currently on its docket. The firm's track record over 7879 career applications provides a reliable benchmark for its 82.06 percent allowance rate in the pharmaceutical field.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 3 (10%) |
| §103 only | 8 (26%) |
| §112 only | 3 (10%) |
| Double-patenting + other | 6 (19%) |
| Multi-statute (no §101) | 10 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, AYAAN A | 4 | 38.4% | +35.6% |
| LEE, WILLIAM Y | 2 | 47.9% | +34.1% |
| DICUIA, JONATHAN ANGELO | 1 | 52.9% | +48.8% |
| UPCHURCH, DAVID M | 1 | 73.7% | +18.0% |
| HOLLOMAN, NANNETTE | 1 | 60.7% | +22.8% |
| ELDRED, JOHN W | 1 | 77.8% | +8.1% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| SHAKERI, HADI | 1 | 62.1% | +37.0% |
| GUILLERMETY, JUAN M | 1 | 72.6% | +14.1% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17187652 | FLEXIBLE BIPOLAR ELECTRODE AND METHODS OF MANUFACTURING AND USE FOR TREATING MEDICAL CONDITIONS INCLUDING OBESITY AND CONSTIPATION | RHODES, NORA W | 73d overdue |
| 18277838 | USE OF GLYCOPROTEIN ACETYLS FOR DETERMINING THE RISK OF DEVELOPING ATRIAL FIBRILLATION AND/OR FLUTTER | GZYBOWSKI, MICHAEL STANLEY | 9d overdue |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | FRITCHMAN, REBECCA M | 9d overdue |
| 18869920 | A GRIP DESIGN WITH AN INSERT MANUFACTURED IN ONE PIECE BY INJECTION | ELDRED, JOHN W | 8d |
| 18087767 | SYSTEMS AND METHODS FOR CONTROLLING FLOW OF THERAPEUTIC AGENT DELIVERED TO AN INFUSION CATHETER | PATEL, SHEFALI DILIP | 28d |
| 19249729 | ROLLER PLATE | DICUIA, JONATHAN ANGELO | — |
| 19120187 | A MULTI-PURPOSE TACTICAL UNIFORM LOCK THAT IS EASILY ATTACHED AND DETACHED | UPCHURCH, DAVID M | — |
| 18838985 | GUN-SHAPED SCREWING APPARATUS WHICH COMPRISES A TOOLBOX WITHIN AND WHICH CAN BE USED FOR THE ASSEMBLY OF FIREARM ACCESORIES | SHAKERI, HADI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16513068 | EXTENDED RELEASE FORMULATIONS OF CANNABINOIDS | ALAM, AYAAN A | 91d overdue |
| 18739123 | PRINTING FROM A HANDHELD DEVICE VIA A REMOTE SERVER | GUILLERMETY, JUAN M | 88d overdue |
| 16513238 | MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS | ALAM, AYAAN A | 45d overdue |
| 19249729 | ROLLER PLATE | DICUIA, JONATHAN ANGELO | — |
| 19120187 | A MULTI-PURPOSE TACTICAL UNIFORM LOCK THAT IS EASILY ATTACHED AND DETACHED | UPCHURCH, DAVID M | — |
| 19064180 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | HOLLOMAN, NANNETTE | — |
| 18895929 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | BLUMEL, BENJAMIN P | — |
| 18838985 | GUN-SHAPED SCREWING APPARATUS WHICH COMPRISES A TOOLBOX WITHIN AND WHICH CAN BE USED FOR THE ASSEMBLY OF FIREARM ACCESORIES | SHAKERI, HADI | — |
| Art Unit | Apps |
|---|---|
| 1611 | 4 |
| 1623 | 2 |
| 1645 | 2 |
| 3783 | 2 |
| 3784 | 1 |
| 3677 | 1 |
| 3641 | 1 |
| 2682 | 1 |
| 1636 | 1 |
| 1798 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19249729 | ROLLER PLATE | Harambe System LLC | DICUIA, JONATHAN ANGELO | 3784 | §103§112 | Non-Final OA | — | Pending | Jun 25, 2025 |
| 19120187 | A MULTI-PURPOSE TACTICAL UNIFORM LOCK THAT IS EASILY ATTACHED AND DETACHED | Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi | UPCHURCH, DAVID M | 3677 | §102§112 | Non-Final OA | — | Pending | Apr 10, 2025 |
| 19064180 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. | HOLLOMAN, NANNETTE | §102DP | Non-Final OA | — | Pending | Feb 26, 2025 | |
| 18869920 | A GRIP DESIGN WITH AN INSERT MANUFACTURED IN ONE PIECE BY INJECTION | Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi | ELDRED, JOHN W | 3641 | §103§112 | Final Rejection | 8d | Pending | Nov 27, 2024 |
| 18895929 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (Uk) Limited | BLUMEL, BENJAMIN P | §112DP | Non-Final OA | — | Pending | Sep 25, 2024 | |
| 18838985 | GUN-SHAPED SCREWING APPARATUS WHICH COMPRISES A TOOLBOX WITHIN AND WHICH CAN BE USED FOR THE ASSEMBLY OF FIREARM ACCESORIES | Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi | SHAKERI, HADI | §103§112 | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18739123 | PRINTING FROM A HANDHELD DEVICE VIA A REMOTE SERVER | Quest Diagnostics Investments LLC | GUILLERMETY, JUAN M | 2682 | §103 | Non-Final OA | 88d overdue | Pending | Jun 10, 2024 |
| 18568249 | MACROCYCLIC TAK1 INHIBITORS | Aqilion AB | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18285063 | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | TriSalus Life Sciences, Inc. | HUDSON, AMY ROSE | 1636 | §103DP | Final Rejection | — | Pending | Sep 29, 2023 |
| 18277838 | USE OF GLYCOPROTEIN ACETYLS FOR DETERMINING THE RISK OF DEVELOPING ATRIAL FIBRILLATION AND/OR FLUTTER | Nightingale Health Oyj | GZYBOWSKI, MICHAEL STANLEY | 1798 | §101§103 | Final Rejection | 9d overdue | Pending | Aug 18, 2023 |
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | 4TEEN4 Pharmaceuticals GmbH | KARUNASENA, ENUSHA | 1645 | §112DP | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18198228 | Method and Apparatus for Storing Energy | King Saud University | NASSER, ROBERT L | 3992 | §112Other | Non-Final OA | 50d | Pending | May 16, 2023 |
| 18036733 | METHOD FOR ASSISTING DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR DETERMINING SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR COLLECTING DATA FOR USE IN DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR DIAGNOSING SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, IN VITRO METHOD FOR ASSISTING DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, ... | Public University Corporation Nagoya City University | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§112 | Final Rejection | — | Pending | May 12, 2023 |
| 18027883 | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | TriSalus Life Sciences, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | 32d overdue | Pending | Mar 22, 2023 |
| 18087508 | SYSTEMS AND METHODS FOR SELECTIVELY INDUCING VASOCONSTRICTION TO INCREASE THERAPEUTIC UPTAKE IN TISSUE | TriSalus Life Sciences, Inc. | JIAN, SHIRLEY XUEYING | 3792 | §102§103§112 | Non-Final OA | — | Pending | Dec 22, 2022 |
| 18087767 | SYSTEMS AND METHODS FOR CONTROLLING FLOW OF THERAPEUTIC AGENT DELIVERED TO AN INFUSION CATHETER | TriSalus Life Sciences, Inc. | PATEL, SHEFALI DILIP | 3783 | §102§103§112 | Non-Final OA | 28d | Pending | Dec 22, 2022 |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | Nightingale Health Oyj | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 9d overdue | Pending | Dec 16, 2022 |
| 17992433 | THERAPEUTIC TREATMENT DEVICE WITH BRAIDED-STRAND MICROVALVE OCCLUDER HAVING MODIFIED FILTER COATING | TriSalus Life Sciences, Inc. | HOUSTON, ELIZABETH | 3771 | §102§103§112 | Final Rejection | — | Pending | Nov 22, 2022 |
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | 4TEEN4 Pharmaceuticals GmbH | WEN, SHARON X | 1641 | §103§112DP | Final Rejection | 45d overdue | Pending | Nov 10, 2022 |
| 17923786 | Uses and Formulations of Cannabinoids | Add Advanced Drug Delivery Technologies Ltd. | LEE, WILLIAM Y | 1623 | §103§112DP | Non-Final OA | — | Pending | Nov 07, 2022 |
| 17970329 | THERAPEUTIC TREATMENT DEVICE WITH BRAIDED MICROVALVE OCCLUDER HAVING COLLAPSIBLE COVER | TriSalus Life Sciences, Inc. | RADOMSKI, MARTIN ADAM | 3783 | §102§103 | Final Rejection | — | Pending | Oct 20, 2022 |
| 17802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | 4TEEN4 Pharmaceuticals GmbH | AEDER, SEAN E | 1642 | §103Other | Final Rejection | — | Pending | Aug 26, 2022 |
| 17622187 | DIGITAL CERTIFICATE PROCESSING METHOD, GATEWAY, DEVICE, SYSTEM, MEDIUM, AND PROGRAM PRODUCT | Antpool Technologies Limited | QAYYUM, ZESHAN | 3697 | §112 | Final Rejection | — | Pending | Dec 22, 2021 |
| 17610127 | METHODS AND SYSTEMS FOR PROTEIN ENGINEERING AND PRODUCTION | Labgenius Ltd. | PLAYER, ROBERT AUSTIN | 1686 | §101§103 | Final Rejection | — | Pending | Nov 09, 2021 |
| 17187652 | FLEXIBLE BIPOLAR ELECTRODE AND METHODS OF MANUFACTURING AND USE FOR TREATING MEDICAL CONDITIONS INCLUDING OBESITY AND CONSTIPATION | Newuro, B.V. | RHODES, NORA W | 3794 | §102§103 | Final Rejection | 73d overdue | Pending | Feb 26, 2021 |
| 17081189 | MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS | Glatt GmbH | ALAM, AYAAN A | 1611 | §103 | Final Rejection | — | Pending | Oct 27, 2020 |
| 17081170 | MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS | Glatt GmbH | ALAM, AYAAN A | 1611 | §103 | Final Rejection | — | Pending | Oct 27, 2020 |
| 16513238 | MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS | Glatt GmbH | ALAM, AYAAN A | 1611 | §103 | Final Rejection | 45d overdue | Pending | Jul 16, 2019 |
| 16513068 | EXTENDED RELEASE FORMULATIONS OF CANNABINOIDS | Glatt GmbH | ALAM, AYAAN A | 1611 | §103 | Non-Final OA | 91d overdue | Pending | Jul 16, 2019 |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | 4TEEN4 Pharmaceuticals GmbH | CHEONG, CHEOM-GIL | 1645 | §101 | Non-Final OA | — | Pending | Oct 22, 2018 |
| 12998180 | MULTIPARTICULATE TABLET AND METHOD FOR THE PRODUCTION THEREOF | Add Technologies Ltd. | BAZARGANI, ARYA AHMADI | 1600 | §103 | Final Rejection | — | Pending | Mar 24, 2011 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial